Search
for

    Research

    5 / 890 results

    Community Join

    5 / 9 results

      community Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs

       3 upvotes 3 years ago
      The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

      community European release of clascoterone

       13 upvotes 5 months ago
      Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

      community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!

       4 upvotes 1 year ago
      A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

      community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?

      in Chat  45 upvotes 9 months ago
      Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

      community How many years can we expect PP405 to be on the market

       11 upvotes 1 year ago
      PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.